ABUS Arbutus Biopharma Corporation

5.55
-0.10  -2%
Previous Close 5.65
Open 5.75
Price To book 1.74
Market Cap 305399822
Shares 55,026,995
Volume 482,119
Short Ratio 5.34
Av. Daily Volume 106,221

SEC filingsSee all SEC filings

  1. SC 13D - General statement of acquisition of beneficial ownership 171086686
  2. 8-K - Current report 171073237
  3. 8-K - Current report 171028974
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 171006188
  5. 8-K - Current report 171004769

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 top-line data due 3Q 2017 - entitled to low to mid-single-digit royalty payments on sales of patisiran by Alnylam.
Patisiran APOLLO
Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR
Phase 2 trial to be initiated 4Q 2017.
AB-423 (MAD)
Hepatitis B (HBV)
Phase 2 Cohort 4 data due September 2017.
ARB-1467
Hepatitis B (HBV)
Phase 1/2 data released July 2016. Intends to explore partnership opportunities to enable further study
TKM-PLK1
Hepatocellular carcinoma (HCC)